PMID- 17717057
OWN - NLM
STAT- MEDLINE
DCOM- 20081118
LR  - 20220317
IS  - 1473-0480 (Electronic)
IS  - 0306-3674 (Linking)
VI  - 42
IP  - 9
DP  - 2008 Sep
TI  - Neutralisation of muscle tumour necrosis factor alpha does not attenuate 
      exercise-induced muscle pain but does improve muscle strength in healthy male 
      volunteers.
PG  - 758-62
AB  - OBJECTIVE: Inflammatory mediators, such as tumour necrosis factor alpha 
      (TNFalpha), may contribute to delayed-onset muscle soreness. The effect of 
      neutralising TNFalpha with etanercept, a soluble TNFalpha receptor, on 
      delayed-onset muscle soreness (DOMS) induced in the quadriceps muscle was 
      analysed. DESIGN: On two separate occasions at least 6 weeks apart, etanercept 25 
      mg or vehicle was given subcutaneously 1 hour before unaccustomed exercise to 12 
      healthy men in a randomised double-blind cross-over format. To induce DOMS, 
      subjects completed 4 sets of 15 repetitions at 80% of their one-repetition 
      maximum (1RM), using a 45 degrees inclined leg press. Muscle soreness was 
      assessed using a 100-mm visual analogue scale (VAS), and pressure pain threshold 
      (PPT) on the thigh before and 24, 48 and 72 hours after exercise. Changes in the 
      subject's muscle strength were detected by reassessing the subject's 1RM 24, 48 
      and 72 hours after exercise. RESULTS: Muscle strength decreased 24 and 48 hours 
      after exercise regardless of agent administered (analysis of variance, p<0.001). 
      At 72 hours after exercise, muscle strength was significantly greater (p<0.01) 
      after etanercept than after placebo. The exercise protocol induced significant 
      DOMS for up to 72 hours, as reflected by reduced PPT and increased VAS scores 
      (p<0.001). Etanercept had no effect on PPT or VAS. CONCLUSION: TNFalpha does not 
      affect muscle soreness associated with unaccustomed exercise, but may improve the 
      recovery of muscle function.
FAU - Rice, T L
AU  - Rice TL
AD  - Brain Function Research Unit, School of Physiology, University of the 
      Witwatersrand, Johannesburg, South Africa.
FAU - Chantler, I
AU  - Chantler I
FAU - Loram, L C
AU  - Loram LC
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20070823
PL  - England
TA  - Br J Sports Med
JT  - British journal of sports medicine
JID - 0432520
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - EC 2.7.3.2 (Creatine Kinase)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Creatine Kinase/blood
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Etanercept
MH  - Exercise/*physiology
MH  - Humans
MH  - Immunoglobulin G/*pharmacology
MH  - Male
MH  - Muscle Strength/*physiology
MH  - Muscle, Skeletal/*physiology
MH  - Pain/etiology/prevention & control
MH  - Pain Measurement
MH  - Receptors, Tumor Necrosis Factor
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
EDAT- 2007/08/25 09:00
MHDA- 2008/11/19 09:00
CRDT- 2007/08/25 09:00
PHST- 2007/08/25 09:00 [pubmed]
PHST- 2008/11/19 09:00 [medline]
PHST- 2007/08/25 09:00 [entrez]
AID - bjsm.2007.038067 [pii]
AID - 10.1136/bjsm.2007.038067 [doi]
PST - ppublish
SO  - Br J Sports Med. 2008 Sep;42(9):758-62. doi: 10.1136/bjsm.2007.038067. Epub 2007 
      Aug 23.